Business
Update on Novel Sulforaphane Analogues
Update on Novel Sulforaphane Analogues.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 6147G Evgen Pharma PLC 05 March 2018 \n\n \n\n\n\n\nFor immediate release\n\n\n5 March 2018\n\n\n\n\n \n\n\n \n\n\n\n\n \n \n \n \n \nEvgen Pharma plc \n (\"Evgen Pharma\" or \"the Company\")\n \nUpdate on novel sulforaphane analogues\n \nEvgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce an update on the screening at the University of Liverpool of the Company's novel analogues of sulforaphane.\n \nEvgen Pharma acquired exclusive worldwide rights to the analogues from the University of Seville in 2015 as part of the Company's strategy to secure a leading position in the intellectual property around sulforaphane-based drugs.\n \nResearchers at the University of Liverpool evaluated 41 analogues, which represent new chemical entities based on sulforaphane's core structure. The analogues were assessed for their cytotoxic potential against a breast cancer cell line and for their ability to activate Nrf2, which is considered to have a key role in sulforaphane's mechanism of action against neurological conditions.\n \nThe activity of the analogues was compared with SFX-01, the Company's lead product which is currently in two Phase II clinical studies in breast cancer and in subarachnoid haemorrhage.\n \nThe headline findings from the research work are that 21 of the analogues are at least twice as cytotoxic against (that is, able to eliminate) breast cancer cells as SFX-01, with the most potent being eight-fold more cytotoxic, and that none of the analogues are as potent as SFX-01 as an activator of Nrf2.\n \nThe results suggest that some of the analogues merit further study as anti-cancer agents and they also provide reassurance that SFX-01, as a synthesised and stabilised copy of naturally occurring sulforaphane, is the optimal sulforaphane-based active for development in subarachnoid haemorrhage and potentially other neurological indications.\n \nWhilst the Company is focused on progressing its core clinical programmes of SFX-01, it will explore all options to further evaluate the analogues, especially with regard to their capacity specifically to target cancer stem cells in breast cancer and other solid tumours. Ultimately,...